Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: Implications for the development of novel therapeutics for bipolar disorder

Neuropsychobiology

Volumn 55, Issue 3-4, 2007, Pages 123-131

  Einat, Haim ^a   Yuan, Peixiong ^b   Szabo, Steven T ^b   Dogra, Samriti ^b   Manji, Husseini K ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Affective disorders; Animal model; Depression; Growth associated protein of 43 kDa; Protein kinase C; Treatment

Indexed keywords

AMPHETAMINE; NEUROMODULIN; PROTEIN KINASE C; TAMOXIFEN;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HYPERACTIVITY; MALE; MANIA; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME INHIBITORS; EXPLORATORY BEHAVIOR; GAP-43 PROTEIN; MALE; MOTOR ACTIVITY; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TIME FACTORS;

EID: 34548433808     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106054     Document Type: Article

References (80)

1. Manji HK, Lenox RH: Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 2000;48:518-530.
2. Bezchlibnyk Y, Young LT: The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry 2002;47:135-148.
3. Coyle JT, Duman RS: Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003;38:157-160.
4. Payne JL, Quiroz JA, Gould TD, Zarate CA, Manji HK: Neurobiology of bipolar disorder; in Charney DS, Nestler EJ (eds): Neurobiology of Mental Illness. Oxford, Oxford University Press, 2004, pp 397-420.
5. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-614.
6. Stabel S, Parker PJ: Protein kinase C. Pharmacol Ther 1991;51:71-95.
7. Newton AC: Protein kinase C: structure, function, and regulation. J Biol Chem 1995;270:28495-28498.
8. Iannazzo L: Involvement of B-50 (GAP-43) phosphorylation in the modulation of transmitter release by protein kinase C. Clin Exp Pharmacol Physiol 2001;28:901-904.
9. MacDonald JF, Kotecha SA, Lu WY, Jackson MF: Convergence of PKC-dependent kinase signal cascades on NMDA receptors. Curr Drug Targets 2001;2:299-312.
10. Nogues X: Protein kinase C, learning and memory: a circular determinism between physiology and behaviour. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:507-529.
11. Ramakers GM, Pasinelli P, Hens JJ, Gispen WH, De Graan PN: Protein kinase C in synaptic plasticity: changes in the in situ phosphorylation state of identified pre- and postsynaptic substrates. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:455-486.
12. Huang KP: Role of protein kinase C in cellular regulation. Biofactors 1990;2:171-178.
13. Kraft AS, Anderson WB: Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane. Nature 1983;301:621-623.
14. Bitran JA, Potter WZ, Manji HK, Gusovsky F: Chronic Li+ attenuates agonist- and phorbol ester-mediated Na+/H+ antiporter activity in HL-60 cells. Eur J Pharmacol 1990;188:193-202.
15. Manji HK, Etcheberrigaray R, Chen G, Olds JL: Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 1993;61:2303-2310.
16. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ: Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994;63:2361-2364.
17. Lenox RH, Watson DG, Patel J, Ellis J: Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992;570:333-340.
18. Goodwin FK, Jamison KR: Manic Depressive Illness, ed 1. New York, Oxford University Press, 1990.
19. Fibiger HC: Neurobiology of depression: focus on dopamine; in Gessa GL, Fratta W, Pani L, Serra G (eds): Depression and Mania: From Neurobiology to Treatment. Adv Biochem Psychopharmacol. New York, Raven Press, 1995, vol 49, pp 1-18.
20. Einat H, Kofman O, Belmaker RH: Animal models of bipolar disorder: from a single episode to progressive cycling models; in Myslobodsky M, Weiner I (eds): Contemporary Issues in Modeling Psychopharmacology. Boston, Kluwer Academic Publishers, 2000, pp 165-180.
21. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R, Koester S, Lederhendler I, Meaney M, Robbins T, Winsky L, Zalcman S: Preclinical models: status of basic research in depression. Biol Psychiatry 2002;52:503-528.
22. Post RM, Contel NR: Cocaine-induced behavioral sensitization: a model for recurrent manic illness; in Perris C, Struwe G, Jansson B (eds): Biological Psychiatry. Amsterdam, Elsevier, 1981, pp 746-749.
23. Giambalvo CT: Protein kinase C and dopamine transport. 2. Effects of amphetamine in vitro. Neuropharmacology 1992;31:1211-1222.
24. Gnegy ME, Hong P, Ferrell ST: Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res 1993;20:289-298.
25. Iwata SI, Hewlett GH, Ferrell ST, Kantor L, Gnegy ME: Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine. J Pharmacol Exp Ther 1997;283:1445-1452.
26. Iwata S, Hewlett GH, Gnegy ME: Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Synapse 1997;26:281-291.
27. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK: A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000;57:95-97.
28. Einat H, Belmaker RH, Manji H: New approaches to modeling bipolar disorder - from face to construct validity. Psychopharmacol Bull 2003;37:47-63.
29. Einat H: Modelling facets of mania - new directions related to the notion of endophenotypes. J Psychopharmacol 2006;20:714-722.
30. Einat H, Shaldubina A, Bersudsky Y, Belmaker RH: Prospectives for the development of animal models for the study of bipolar disorder; in Soares JC, Young RC (eds): Bipolar Disorders: Basic Mechanisms and Therapeutic Implications, 2nd ed. New York, Informa Healthcare, 2000, pp 23-38.
31. O'Brian CA, Ward NE, Anderson BW: Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J Natl Cancer Inst 1988;80:1628-1633.
32. Baltuch GH, Couldwell WT, Villemure JG, Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines: a comparison between staurosporine and tamoxifen. Neurosurgery 1993;33:495-501; discussion 501.
33. Oehrlein SA, Parker PJ, Herget T: Phosphorylation of GAP-43 (growth-associated protein of 43 kDa) by conventional, novel and atypical isotypes of the protein kinase C gene family: differences between oligopeptide and polypeptide phosphorylation. Biochem J 1996;317:219-224.
34. Dalton JC, Vickers GJ, Roberts DC: Increased self-administration of cocaine following haloperidol: sex-dependent effects of the antiestrogen tamoxifen. Pharmacol Biochem Behav 1986;25:497-501.
35. Antoniou K, Kafetzopoulos E, Papadopoulou-Daifoti Z, Hyphantis T, Marselos M: D-Amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats. Neurosci Biobehav Rev 1998;23:189-196.
36. Golani I, Einat H, Tchernichovski O, Teitelbaum P: Keeping the body straight in the unconstrained locomotion of normal and dopamine-stimulant- treated rats. J Mot Behav 1997;29:99-112.
37. Bowling SL, Bardo MT: Locomotor and rewarding effects of amphetamine in enriched, social, and isolate reared rats. Pharmacol Biochem Behav 1994;48:459-464.
38. Decker S, Grider G, Cobb M, Li XP, Huff MO, El-Mallakh RS, Levy RS: Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:455-462.
39. Chaouloff F, Elghozi JL, Guezennec Y, Laude D: Effects of conditioned running on plasma, liver and brain tryptophan and on brain 5-hydroxytryptamine metabolism of the rat. Br J Pharmacol 1985;86:33-41.
40. Aloisi AM, Casamenti F, Scali C, Pepeu G, Carli G: Effects of novelty, pain and stress on hippocampal extracellular acetylcholine levels in male rats. Brain Res 1997;748:219-226.
41. Tejero-Diez P, Rodriguez-Sanchez P, Martin-Cofreces NB, Diez-Guerra FJ: bFGF stimulates GAP-43 phosphorylation at ser41 and modifies its intracellular localization in cultured hippocampal neurons. Mol Cell Neurosci 2000;16:766-780.
42. Van Hooff CO, Holthuis JC, Oestreicher AB, Boonstra J, De Graan PN, Gispen WH: Nerve growth factor-induced changes in the intracellular localization of the protein kinase C substrate B-50 in pheochromocytoma PC12 cells. J Cell Biol 1989;108:1115-1125.
43. Krivanek J: Protein kinase C in the parabrachial nucleus of rats during conditioned taste aversion induced by amphetamine. Neurosci Lett 1997;236:17-20.
44. Robinson PJ: The role of protein kinase C and its neuronal substrates dephosphin, B-50, and MARCKS in neurotransmitter release. Mol Neurobiol 1991;5:87-130.
45. Cowell RM, Kantor L, Hewlett GH, Frey KA, Gnegy ME: Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur J Pharmacol 2000;389:59-65.
46. Kantor L, Gnegy ME: Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 1998;284:592-598.
47. Zhou J, He R, Johnson KM, Ye Y, Kozikowski AP: Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization. J Med Chem 2004;47:5821-5824.
48. Spencer SA, Schuh SM, Liu WS, Willard MB: GAP-43, a protein associated with axon growth, is phosphorylated at three sites in cultured neurons and rat brain. J Biol Chem 1992;267:9059-9064.
49. Huang KP, Huang FL, Chen HC: Hypoxia/ ischemia induces dephosphorylation of rat brain neuromodulin/GAP-43 in vivo. J Neurochem 1999;72:1294-1306.
50. Coggins PJ, Zwiers H: Evidence for a single protein kinase C-mediated phosphorylation site in rat brain protein B-50. J Neurochem 1989;53:1895-1901.
51. Park YH, Kantor L, Guptaroy B, Zhang M, Wang KK, Gnegy ME: Repeated amphetamine treatment induces neurite outgrowth and enhanced amphetamine-stimulated dopamine release in rat pheochromocytoma cells (PC12 cells) via a protein kinase C- and mitogen activated protein kinase-dependent mechanism. J Neurochem 2003;87:1546-1557.
52. Young E, Cesena T, Meiri KF, Perrone-Bizzozero NI: Changes in protein kinase C (PKC) activity, isozyme translocation, and GAP-43 phosphorylation in the rat hippocampal formation after a single-trial contextual fear conditioning paradigm. Hippocampus 2002;12:457-464.
53. Willner P: Animal models of depression: validity and applications; in Gessa GL, Fratta W, Pani L, Serra G (eds): Depression and Mania: From Neurobiology to Treatment. Adv Biochem Psychopharmacol. New York, Raven Press, 1995, vol 49, pp 19-42.
54. Mandlekar S, Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-477.
55. Jordan VC: Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer. J Natl Cancer Inst 1992;84:231-234.
56. Jordan VC: Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003;2:205-213.
57. Goekjian PG, Jirousek MR: Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001;10:2117-2140.
58. Wheeler GD: Ruboxistaurin (Eli Lilly). IDrugs 2003;6:159-163.
59. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR Jr, Blatt J, Nicholson S, Packer RJ, Allen JC, Cisneros A, Jordan VC: A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997;3:1109-1115.
60. Mastronardi L, Puzzilli F, Ruggeri A: Tamoxifen as a potential treatment of glioma. Anticancer Drugs 1998;9:581-586.
61. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo ML, Masri L, Law RE, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996;2:619-622.
62. Browman KE, Kantor L, Richardson S, Badiani A, Robinson TE, Gnegy ME: Injection of the protein kinase C inhibitor Ro31-8220 into the nucleus accumbens attenuates the acute response to amphetamine: tissue and behavioral studies. Brain Res 1998;814:112-119.
63. Steketee JD: Intra-ventral tegmental area administration of H7 delays, but does not prevent the development of cocaine-induced sensitization. Brain Res Bull 1997;43:565-571.
64. Steketee JD: Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport 1994;6:69-72.
65. Steketee JD: Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: behavioral and in vivo microdialysis studies. Neuropharmacology 1993;32:1289-1297.
66. Kamei J, Mizoguchi H, Narita M, Tseng LF: Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opin Investig Drugs 2001;10:1653-1664.
67. Cervo L, Mukherjee S, Bertaglia A, Samanin R: Protein kinases A and C are involved in the mechanisms underlying consolidation of cocaine place conditioning. Brain Res 1997;775:30-36.
68. Einat H, Chen G, Manji H: Possible involvement of protein kinase C (PKC) in bipolar disorder and its treatment. Harefuah 2004;143:420-425.
69. Einat H, Manji HK: Cellular plasticity cascades: gene to behavior pathways in animal models of bipolar disorder. Biol Psychiatry 2006;59:1960-1971.
70. Birnbaum SG, Yuan PX, Wang M, Vijayraghavan S, Bloom AK, Davis DJ, Gobeske KT, Sweatt JD, Manji HK, Arnsten AF: Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science 2004;306:882-884.
71. Menniti FS, Baum MJ: Differential effects of estrogen and androgen on locomotor activity induced in castrated male rats by amphetamine, a novel environment, or apomorphine. Brain Res 1981;216:89-107.
72. West CH, Michael RP: Time-dependent modulation by estrogen of amphetamine-induced hyperactivity in male rats. Pharmacol Biochem Behav 1986;25:919-923.
73. Castner SA, Xiao L, Becker JB: Sex differences in striatal dopamine: in vivo microdialysis and behavioral studies. Brain Res 1993;610:127-134.
74. Earley CJ, Leonard BE: Behavioural studies on the effects of d-amphetamine and estradiol benzoate alone and in combination. Psychopharmacology (Berl) 1978;56:179-183.
75. Friedman E, Hoau Yan W, Levinson D, Connell TA, Singh H: Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993; 33:520-525.
76. Hahn CG, Umapathy, Wang HY, Koneru R, Levinson DF, Friedman E: Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res 2005;39:355-363.
77. Wang HY, Friedman E: Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996;40:568-575.
78. Giambalvo CT: Protein kinase C and dopamine transport-1. Effects of amphetamine in vivo. Neuropharmacology 1992;31:1201-1210.
79. Lenox RH, Wang L: Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. Mol Psychiatry 2003;8:135-144.
80. Manji HK, Lenox RH: Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999;46:1328-1351.